Well, of course, there are novel agents, and amyloid is just a part of the equation, one of the stories in this very large tapestry that we call Alzheimer’s. Obviously, there are other drugs that are geared toward tau and other pathogens that we’re picking up in the Alzheimer’s space. But for the time being, for where it stands in 2025, and I think at least through 2026, anti-amyloid pharmacotherapy is considered the gold standard disease-modifying approach...
Well, of course, there are novel agents, and amyloid is just a part of the equation, one of the stories in this very large tapestry that we call Alzheimer’s. Obviously, there are other drugs that are geared toward tau and other pathogens that we’re picking up in the Alzheimer’s space. But for the time being, for where it stands in 2025, and I think at least through 2026, anti-amyloid pharmacotherapy is considered the gold standard disease-modifying approach. So patients who do have a mild Alzheimer condition or a mild cognitive impairment due to Alzheimer’s need to be availed of this treatment. Unfortunately, many patients aren’t because of all the barriers that I’ve just discussed. But hopefully more and more patients will proceed and get tested to be treated appropriately. What we’re trying to do in our community where I’m based, South Florida, Miami, Jupiter, is we’re trying to create somewhat of a spoken hub model, meaning if you’re a private practice neurologist or you’re a primary care physician or a geriatrician, we’re trying to make our group as amenable and as receptive as possible to being able to bring in those referrals, do the workup, initiate the treatment, maintain the treatment as requested, and then get the patient back to that private practice neurologist or geriatrician or geri-psych wherever they came from. So, a lot of this, again, requires good outreach within the community wherever you practice.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
